Shanghai Hengrui Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-12-04
- Employees
- -
- Market Cap
- -
- Website
- http://www.shhrp.com
Clinical Trials
51
Active:9
Completed:10
Trial Phases
3 Phases
Phase 1:32
Phase 2:14
Phase 3:5
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
Phase 1
32 (62.7%)Phase 2
14 (27.5%)Phase 3
5 (9.8%)A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Phase 2
Recruiting
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: Adebelimab InjectionDrug: Ametinib Mesylate Tablets
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 400
- Registration Number
- NCT06895928
- Locations
- 🇨🇳
Shanxi Cancer hospital, Taiyuan, Shanxi, China
A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism
Phase 1
Active, not recruiting
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: [14C] SHR6508 Injection
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT06877247
- Locations
- 🇨🇳
The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province), Jinan, Shandong, China
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma
Phase 3
Recruiting
- Conditions
- Advanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-12-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT06738251
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT06704828
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy
Phase 2
Recruiting
- Conditions
- Advanced Gynecological Malignancy
- Interventions
- Drug: SHR-A2102 for injection
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06654440
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
No news found